Solana (NASDAQ:HSDT) Releases Quarterly Earnings Results, Beats Expectations By $30.75 EPS

Solana (NASDAQ:HSDT) announced its earnings results on Monday. The company reported $4.25 EPS for the quarter, beating analysts’ consensus estimates of ($26.50) by $30.75, FiscalAI reports. Solana had a negative return on equity of 699.93% and a negative net margin of 679.54%.The company had revenue of $5.23 million during the quarter, compared to analysts’ expectations of $0.14 million.

Here are the key takeaways from Solana’s conference call:

• Solana Company has staked substantially all of its SOL and reported disciplined outperformance in staking yields—6.8% average net yield in Q4 2025 vs a 6.2% system average, and 7.0% YTD 2026 vs 6.0%—generating steady on‑chain revenue.
• Active capital markets and treasury management grew SOL per share by about 14% from the strategy start (Sept 18, 2025) to March 27, 2026, with roughly 2.33 million SOL on hand (Mar 27) and $7M of cash/stablecoins.
• GAAP results show large volatility and non‑cash charges—Q4 operating loss of $201.1M (including $178.3M unrealized digital asset losses)—and Q4 net income of $325.6M was driven by a $526.3M fair‑value gain on PIPE stapled warrants, while FY2025 ended with a $40.9M net loss.
• The company announced strategic growth initiatives—the Anchorage Digital + Kamino tri‑party custody/borrowing arrangement (aimed to unlock an incremental 100–200 bps of yield) and the regional Pacific Backbone low‑latency node build to target Asia‑Pacific institutional services within 12–18 months.

Solana Stock Performance

NASDAQ:HSDT opened at $1.73 on Wednesday. Solana has a 1 year low of $1.63 and a 1 year high of $366.68. The stock has a fifty day moving average price of $2.23 and a two-hundred day moving average price of $5.64. The stock has a market capitalization of $71.45 million, a price-to-earnings ratio of 0.00 and a beta of 1.07.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Solana in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.

Hedge Funds Weigh In On Solana

A number of large investors have recently made changes to their positions in HSDT. Price T Rowe Associates Inc. MD acquired a new stake in Solana in the fourth quarter valued at $46,000. OMERS ADMINISTRATION Corp acquired a new stake in Solana during the fourth quarter worth approximately $88,000. Aristides Capital LLC purchased a new stake in shares of Solana in the fourth quarter valued at $137,000. XTX Topco Ltd acquired a new position in shares of Solana during the 4th quarter valued at about $140,000. Finally, Marshall Wace LLP purchased a new position in Solana during the fourth quarter worth approximately $195,000. Hedge funds and other institutional investors own 18.63% of the company’s stock.

About Solana

Helius Medical Technologies, Inc (NASDAQ: HSDT) is a medical technology company focused on developing and commercializing non‐invasive neuromodulation platforms designed to enhance neurorehabilitation. Its flagship product, the Portable Neuromodulation Stimulator (PoNS®), delivers mild electrical pulses to the tongue to stimulate neural pathways in conjunction with targeted physical therapy. The device is intended to improve neuroplasticity and support recovery in patients with neurological conditions.

The PoNS system is cleared for use in the United States, Canada and the European Union and is prescribed through specialized rehabilitation clinics.